Prof. Dr. Saadettin Kılıçkap

The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

Journal of Chemotherapy, 2024

DOI 10.1080/1120009x.2024.2305066 PMID 38263804 2 citations (Europe PMC) Source : OpenAlex

Association of very deep prostate-specific antigen (PSA) decline with longer radiologic-progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer.

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.16_suppl.e17074 Texte intégral en libre accèsSource : OpenAlex

Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer

Clinical Genitourinary Cancer, 2024

DOI 10.1016/j.clgc.2024.102228 PMID 39461025 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors

Clinical Genitourinary Cancer, 2024

DOI 10.1016/j.clgc.2024.102163 PMID 39126823 1 citation (Europe PMC) Source : ORCID

A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

Cancer Cell, 2024

DOI 10.1016/j.ccell.2023.12.004 PMID 38181795 66 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

COVID-19 pandemic: changes in cancer admissions

BMJ Supportive and Palliative Care, 2024

DOI 10.1136/bmjspcare-2020-002468 PMID 32665259 21 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

Nature Medicine, 2024

DOI 10.1038/s41591-024-03008-4 PMID 38898120 29 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study

Current Medical Research and Opinion, 2024

DOI 10.1080/03007995.2024.2359026 PMID 38809230 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors

Supportive Care in Cancer, 2024

DOI 10.1007/s00520-024-08681-2 PMID 38937345 7 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study

Journal of Thoracic Oncology, 2024

DOI 10.1016/j.jtho.2024.06.008 PMID 38880172 53 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer

Cancers, 2024

DOI 10.3390/cancers16010156 PMID 38201583 8 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab

JTO Clinical and Research Reports, 2024

DOI 10.1016/j.jtocrr.2024.100675 PMID 39399157 11 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Vaccination attitudes and practices of physicians and nurses in adult oncology settings

Journal of Research in Pharmacy, 2024

DOI 10.29228/jrp.722 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID

Immune checkpoints blockade therapies' efficacy and toxicity in patients with impaired renal function in metastatic bladder cancer.

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.4_suppl.594 Texte intégral en libre accèsSource : OpenAlex

1271P Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC

Annals of Oncology, 2024

DOI 10.1016/j.annonc.2024.08.1328 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Carcinoid Syndrome

Springer eBooks, 2024

DOI 10.1007/978-3-031-56968-5_29 Source : OpenAlex

IMMUNOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CARCINOMA

Turkiye Klinikleri eBooks, 2024

DOI 10.5336/978-625-395-244-0_p31 Source : OpenAlex

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

The Oncologist, 2023

DOI 10.1093/oncolo/oyad257 PMID 37676712 8 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group ( TOG ) study

Cancer Medicine, 2023

DOI 10.1002/cam4.6869 PMID 38140782 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Journal of Cancer Research and Clinical Oncology, 2023

DOI 10.1007/s00432-023-05190-3 PMID 37480524 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

The Lancet Oncology, 2023

DOI 10.1016/s1470-2045(23)00329-7 PMID 37591293 96 citations (Europe PMC) Source : OpenAlex

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis

Journal of Thoracic Oncology, 2023

DOI 10.1016/j.jtho.2023.08.017 PMID 37865896 29 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye

Future Oncology, 2023

DOI 10.2217/fon-2023-0518 PMID 38014519 Texte intégral en libre accèsSource : OpenAlex

Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.16_suppl.9022 3 citations (OpenAlex) Source : OpenAlex

Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

Clinical Genitourinary Cancer, 2023

DOI 10.1016/j.clgc.2022.11.019 PMID 36641357 2 citations (Europe PMC) Source : ORCID

Adjuvant radiotherapy in the management of porocarcinoma with lymphatic micrometastasis

Oncology in Clinical Practice, 2023

DOI 10.5603/ocp.2023.0003 Texte intégral en libre accèsSource : ORCID

Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group

Current Problems in Cancer, 2023

DOI 10.1016/j.currproblcancer.2023.101017 PMID 37845104 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data

Supportive Care in Cancer, 2023

DOI 10.1007/s00520-023-08083-w PMID 37819422 171 citations (Europe PMC) Source : ORCID

Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

International Journal of Cancer, 2023

DOI 10.1002/ijc.34280 PMID 36082448 6 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study

Supportive Care in Cancer, 2023

DOI 10.1007/s00520-023-07652-3 PMID 36856870 7 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Intracerebral de novo arterio-venous malformations as a side effect of bevacizumab

Journal of Oncology Pharmacy Practice, 2023

DOI 10.1177/10781552231171113 PMID 37078175 Source : ORCID

Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

Journal of Immunotherapy and Precision Oncology, 2023

DOI 10.36401/jipo-23-3 PMID 38143956 6 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review,Radiothérapie dirigée sur les métastases de cancer du poumon non à petites cellules en échec sous inhibiteurs de la thyrosine kinase : cas clinique et revue de la littérature

Cancer/Radiotherapie, 2023

DOI 10.1016/j.canrad.2023.06.002 PMID 37827958 Source : ORCID

Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events

Future Oncology, 2023

DOI 10.2217/fon-2023-0014 PMID 37449387 8 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study

Journal of Cancer Research and Clinical Oncology, 2023

DOI 10.1007/s00432-022-04268-8 PMID 35960374 8 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

Anti-Cancer Drugs, 2023

DOI 10.1097/cad.0000000000001463 PMID 36729111 5 citations (Europe PMC) Source : ORCID

230P Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

ESMO Open, 2023

DOI 10.1016/j.esmoop.2023.101418 Texte intégral en libre accèsSource : OpenAlex

Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

Urologia Internationalis, 2023

DOI 10.1159/000528994 PMID 36996793 3 citations (Europe PMC) Source : ORCID

Comparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma.

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.6_suppl.481 Source : OpenAlex

The Prognostic Significance of KIAA1522 Expression in Non-Small-Cell Lung Cancer Patients

Cureus, 2023

DOI 10.7759/cureus.44016 PMID 37746394 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia

Cureus, 2023

DOI 10.7759/cureus.41992 PMID 37492039 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study

Immuno-Oncology Technology, 2023

DOI 10.1016/j.iotech.2023.100692 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Phenotypic and Genetic Features that Differ Between Hereditary and Sporadic Melanoma: Results of a Preliminary Study from a Single Center from Turkey

Dermatology Practical & Conceptual, 2023

DOI 10.5826/dpc.1303a146 PMID 37557112 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Prevalence of EGFR mutations in patients with resected stage I-III non-squamous NSCLC: Results from the EARLY-EGFR study.

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.16_suppl.8531 Source : OpenAlex

Heart Rate Recovery and Chronotropic Response on Exercise in Colorectal Cancer Survivors

European Respiratory Journal, 2023

DOI 10.1183/13993003.congress-2023.pa3398 Source : OpenAlex

P2.06-10 Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

Journal of Thoracic Oncology, 2023

DOI 10.1016/j.jtho.2023.09.556 Texte intégral en libre accèsSource : OpenAlex

600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1

Journal for ImmunoTherapy of Cancer, 2023

DOI 10.1136/jitc-2023-sitc2023.0600 Texte intégral en libre accèsSource : OpenAlex

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal carcinoma

Bosnian Journal of Basic Medical Sciences, 2022

DOI 10.17305/bjbms.2021.7069 PMID 35460397 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients

Pancreas, 2022

DOI 10.1097/mpa.0000000000002167 PMID 37078939 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Journal of Cancer Research and Clinical Oncology, 2022

DOI 10.1007/s00432-022-04252-2 PMID 36048274 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex